Granules Jeedimetla facility located at Hyderabad, Telangana, India has successfully completed the US FDA’s surveillance inspection with zero observations, the company announced through an exchange filing. The inspection was completed between June 19 and June 23.
Jeedimetla facility manufactures Active Pharmaceutical Ingredients (API) and Pharmaceutical Formulation Intermediates (PFIs).
Granules shares
The shares of Granules on Friday closed at Rs 286.95, down by 0.35 per cent.
Sanjana Sanghi: Leading India’s Youth Voice
Festive Travel Boosts India's Petrol Sales To Five-Month High, Diesel Consumption Falls
Mumbai Weather Update: City Wakes Up To Light Rains & Improved Air Quality, More Showers Predicted; AQI In Good Range At 46
Fair Trade Regulator CCI Has No Power To Examine Patent Matter Disputes: Appellate Tribunal NCLAT
